Bernstein analyst Lee Hambright raised the firm’s price target on Abbott to $138 from $133 and keeps an Outperform rating on the shares following a “good quarter.” The firm notes Q3 sales were in-line despite a couple of one-time headwinds. Organic growth was 8.2% led by 13.3% organic growth in Medical Devices, including 26% U.S. Libre growth. Adjusted EPS of $1.21 beat consensus by 1c.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Abbott price target raised to $117 from $107 at Morgan Stanley
- Abbott price target raised to $125 from $120 at Jefferies
- Abbott price target raised to $130 from $125 at Stifel
- Abbott price target raised to $139 from $135 at BTIG
- United Air reports Q3 beat, Amazon unveils nuclear energy pacts: Morning Buzz